Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

Published 07/28/2019, 10:02 PM
Updated 07/09/2023, 06:31 AM

GNC Holdings, Inc. (NYSE:GNC) reported second-quarter 2019 adjusted earnings per share of 13 cents, down 35% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 85.7%.

Reported earnings per share for the quarter came in at 11 cents, down 31.25% year over year.

Revenues

Revenues for the second quarter came in at $534 million, down 13.6% year over year. The top line missed the Zacks Consensus Estimate by 2.9%.

Segmental Details

GNC Holdings reports operations under three segments — U.S. & Canada (including company-owned stores in the United States, Puerto Rico and Canada, franchise stores in the United States, and e-commerce), International (inclusive of franchise locations in approximately 50 countries, The Health Store and China operations) and Manufacturing/Wholesale (comprising manufactured products sold to other segments, third-party contract manufacturing and sales to wholesale partners).

GNC Holdings, Inc. Price, Consensus and EPS Surprise

GNC Holdings, Inc. price-consensus-eps-surprise-chart | GNC Holdings, Inc. Quote

During the reported quarter, GNC Holdings’ revenues from the U.S. & Canada segment fell 8% year over year to $476.1 million. Notably, e-commerce sales accounted for 8.1% of U.S. and Canada revenues, decreasing from 8.3% in the prior-year quarter.

Company-owned net store closures negatively impacted revenues by $14.9 million. Further, a decline of 4.6% in same-store sales led to a fall of $17.5 million in revenues of this segment. Moreover, in domestic franchise locations, same-store sales decreased 1.8% from the year-ago period.

Revenues in the International segment declined 18.9% to $40.9 million for the quarter under review. This downside can be primarily attributed to transfer of the China business to the newly formed joint venture, effective Feb 13, 2019.However, the decline was partially offset by a $0.7-million increase in sales of the company’s international franchisees.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Revenues in the Manufacturing / Wholesale segment registered year-over-year plunge of 64.4% to $18.5 million, excluding intersegment sales. This was mainly due to the transfer of the Nutra manufacturing business to the newly formed manufacturing joint venture with International Vitamin Corporation, effective Mar 1, 2019.

Margins

Gross profit declined 6.7% year over year to $193.7 million. Gross margin expanded 266 bps to 36.3% in the second quarter.

Selling, general and administrative expenses declined 9.3% to $143.8 million. Adjusted operating profit rose 1.4% to $49.9 million and adjusted operating margin expanded 138 bps to 9.3%.

Financial Position

GNC Holdings exited the second quarter with cash and cash equivalents of $95.9 million compared to $137.1 million at the end of the first quarter. Long-term debt was $854.7 million in the quarter under review, down from $888.4 million at the end of the previous quarter.

Year-to-date net cash flow from operating activities totaled $65.3 million compared with $49.1 million from the year-ago period.

Further, the company generated year-to-date free cash flow of $58.9 million compared with $40.8 million in the prior-year quarter.

Our Take

GNC Holdings exited the second quarter of 2019 on a mixed note, as the bottom line surpassed the Zacks Consensus Estimate, while revenues lagged the same.

Each of the three operating segments reported year-over-year sales decline. Despite the negatives, we are optimistic about some second-quarter developments. For instance,the recently launched Lit AF, an enhanced, next-generation, pre-workout dietary supplement in the $135-million Beyond Raw GNC brand, buoys optimism.

We are encouraged to note the expansion of both the margins in the quarter.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank & Key Picks

GNC Holdings currently carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical space are Hologic Inc. (NASDAQ:HOLX) , DENTSPLY SIRONA Inc. (NASDAQ:XRAY) and Teleflex Inc. (NYSE:TFX) .

Hologic is scheduled to release second-quarter 2019 results on Jul 31. The Zacks Consensus Estimate for adjusted EPS is pegged at 61 cents and for revenues stands at $834.6 million. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DENTSPLY SIRONA is scheduled to release second-quarter 2019 results on Aug 2. The Zacks Consensus Estimate for the period’s adjusted EPS is 62 cents and for revenues $1.03 billion. The stock sports a Zacks Rank #1.

Teleflex is expected to release second-quarter 2019 results on Aug 1. The Zacks Consensus Estimate for adjusted EPS in the to-be-reported quarter is $2.59 and for the top line $636.7 million. The stock has a Zacks Rank of 2.

Radical New Technology Creates $12.3 Trillion Opportunity

Imagine buying Microsoft (NASDAQ:MSFT) stock in the early days of personal computers… or Motorola (NYSE:MSI) after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.

See the 7 breakthrough stocks now>>



Teleflex Incorporated (TFX): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Hologic, Inc. (HOLX): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

GNC Holdings, Inc. (GNC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.